## S Chang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7752162/publications.pdf

Version: 2024-02-01

2682572 1872680 42 11 2 6 citations h-index g-index papers 11 11 11 68 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics, 2017, 35, 479-491.	3.3	28
2	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. Current Therapeutic Research, 2020, 93, 100601.	1.2	10
3	Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis – A Cost-Utility Model for the United Kingdom. Value in Health, 2013, 16, A564.	0.3	1
4	Mabthera® (Rituximab) for the Treatment of Severe Granulomatosis With Polyangiitis (Gpa) and Microscopic Polyangiitis (Mpa) – A Cost-Utility Model for the United Kingdom. Value in Health, 2014, 17, A382.	0.3	1
5	The Cost-Effectiveness Of Detecting Arrhythmia With Implantable Loop Recorders In The United State Of America. Value in Health, 2014, 17, A116.	0.3	1
6	Nintedanib Cost-Effectiveness In Idiopathic Pulmonary Fibrosis In The UK. Value in Health, 2016, 19, A553.	0.3	1
7	PRM11 Learning Effect in Economic Evaluations of Health Care Interventions. Value in Health, 2011, 14, A422-A423.	0.3	0
8	Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes. Value in Health, 2013, 16, A549.	0.3	0
9	Efficacy Of Novel Dmards In Early Active Rheumatoid Arthritis: An Indirect Comparison. Value in Health, 2014, 17, A374.	0.3	0
10	AB0432â€Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: an Indirect Comparison. Annals of the Rheumatic Diseases, 2014, 73, 950.2-950.	0.9	0
11	Tocilizumab in Methotrexate-NaÃ⁻ve Rheumatoid Arthritis – A Cost-Utility Model for Slovakia. Value in Health, 2015, 18, A648.	0.3	0